Document:

[NEUROMETRIX LETTERHEAD]

 

May 1, 2008

 

Mr. Gary L. Gregory

31 Deerfield Road

Sherborn, MA 
01770

 

Dear Gary:

 

This letter
confirms your separation from employment with NeuroMetrix, Inc. (the “Company”).

 

This letter
also proposes an agreement between you and the Company.

 

Your
employment with the Company shall terminate effective May 31, 2008.  Until May 31, 2008, the Company shall
pay and provide you any compensation and benefits to which you are entitled
under the terms of the Employment Agreement (as defined below), the Plans and
the Award Agreements (as those terms are defined below) and any applicable
Company plans, programs, policies and procedures through that date.  In addition, the Company shall pay you for all
accrued but unused vacation time through the date of termination of your
employment. The Company shall also provide you with the right to continue group
medical and dental insurance coverage after the termination of your employment
under the law known as “COBRA.”  The
terms for that opportunity will be set forth in a separate written notice.  The termination of other benefits will be
addressed in separate correspondence. 
Basically, your eligibility to participate in any other employee benefit
plans and programs of the Company ceases on or after the termination of your
employment in accordance with applicable benefit plan or program terms and
practices.  The Company shall also
reimburse you for any outstanding, reasonable business expenses that you have incurred
on the Company’s behalf through the termination of your employment, after the
Company’s timely receipt of appropriate documentation pursuant to the Company’s
business expense reimbursement policy. 
The payments and other terms set forth above will not be affected by
whether or not you agree to the terms set forth below.

 

As you know,
the Employment Agreement that you entered into with the Company on or about June 19,
2002 (the “Employment Agreement”), provides that, upon your termination
for any reason other than willful misconduct, you will be eligible to receive
certain benefits subject to your execution of a release agreement with the
Company.  The remainder of this letter
constitutes that release agreement (this
“Agreement”) between you and the Company, which offers those severance
payments and benefits set forth in the Employment Agreement in addition to
certain additional payments.  If you
agree to the terms of this Agreement, you acknowledge that you are entering
into this Agreement voluntarily.  With
those understandings, you and the Company agree as follows:

 

 

1.                                       Termination
of Employment

 

This confirms
that your employment and position with
the Company as its Chief Operating Officer will terminate effective May 31,
2008 (the “Termination Date”). 
You further confirm that you have resigned from any and all other
positions that you hold with the Company as an officer, director or otherwise
effective on the Termination Date.  You
further confirm that you have resigned from any and all positions that you hold
with any affiliate of the Company, including, without limitation, any employee
benefit plan, effective on the Termination Date.

 

2.                                       Severance
Benefits

 

(a)                                  Severance Pay.  The
Company shall pay you severance pay (“Severance Pay”) consisting of the
following:

 

(i)                                     (A) salary
continuation at your final base salary rate of $22,670 per month, and (B) continuation
of your car allowance payment of $600 per month, for the nine-month period from
the date immediately following the Termination Date to and including February 28,
2009 (the “Severance Pay Period”). 
The Company shall make these payments to you on its regular payroll
dates applicable to your position with the Company, provided that
the Company is not obligated to include you on the payroll before this
Agreement becomes effective.  If the
Company does not make one or more payments of Severance Pay on a regular
payroll date because this Agreement has not yet become effective, the Company
shall make all such payments by the first payroll date after this Agreement becomes effective in accordance with Section 21; and

 

(ii)                                  A
lump sum payment equal to $69,810.  This lump sum payment shall be made to you no
later than five (5) business days after the later of the Termination Date
and the Effective Date of this Agreement, as that term is defined in Section 21.

 

(b)                                 Health Benefits.  Your
rights and obligations under COBRA are explained in a separate letter to you
describing your medical and dental insurance continuation rights under
COBRA.  To continue your medical and
dental insurance coverage, you must elect COBRA continuation coverage.  If you elect COBRA continuation coverage and provided that you and your beneficiaries remain eligible for
COBRA continuation coverage, the Company shall continue to pay for medical and
dental insurance premiums for coverage of you and your beneficiaries to the
same extent as if you had remained employed to the end of the Severance Pay
Period.  You will be responsible for the
remaining portion of such coverage as if you remained employed.  You hereby authorize the deduction of the
portion for which you are responsible from your Severance Pay.  If you elect COBRA continuation coverage, you
may continue coverage for yourself and any beneficiaries after the end of the
Severance Pay Period at your own expense for the remainder of the COBRA period,
to the extent you and they remain eligible.

 

2

 

3.                                       Stock
Options

 

All options that you hold to purchase shares of the Company’s common
stock pursuant to the NeuroMetrix, Inc. Amended and Restated 2004 Stock
Option and Incentive Plan or Amended and Restated 1998 Equity Incentive Plan,
in each case, as amended, or any predecessor plan (collectively, the “Plans”)
that are not vested as of your Termination Date shall lapse on that date and
will not be exercisable, except that
17,500 shares of the option granted to you on or about April 1, 2008 and
3,907 shares of the option granted to you on or about June 21, 2004 shall
immediately vest upon the later of the Termination Date and the Effective Date.

 

Additionally,
subject to the effectiveness of this Agreement, you will be entitled to
exercise any or all of the vested portion of the stock option granted to you on
April 1, 2008 at any time on or before the first anniversary of the
Termination Date.  You acknowledge that,
assuming this Agreement becomes effective, the chart attached as Exhibit A contains a complete listing of all
outstanding stock options that will have vested
on or prior to the Termination Date in accordance with the terms of such stock
options under the Plans and under the existing award agreements between the
Company and you relating to such stock options (collectively, the “Award
Agreements”), as modified by this Agreement. 
You also agree that, assuming this Agreement becomes effective, all
outstanding equity awards made by the Company to you that are not listed as
vested on Exhibit A are forfeited as of the Termination Date and that the
vested stock options will expire on the dates set forth in Exhibit A if
they are not exercised on or before such dates, notwithstanding anything to the
contrary contained in the Plans or the Award Agreements.  Except as otherwise agreed herein, the
exercise of any vested stock options shall continue to be subject to the
existing terms of the Plans and the Award Agreements.

 

4.                                       Tax
Treatment

 

The Company
shall undertake to make deductions, withholdings and tax reports with respect
to payments and benefits under this Agreement to the extent that it reasonably
and in good faith determines that it is required to make such deductions,
withholdings and tax reports.  Payments
under this Agreement shall be in amounts net of any such deductions or
withholdings.  Nothing in this Agreement
shall be construed to require the Company to make any payments to compensate
you for any adverse tax effect associated with any payments or benefits or for
any deduction or withholding from any payment or benefit.

 

5.                                       Return
of Property

 

You agree
that, on the Termination Date, you will, to the best of your knowledge, return
to the Company all Company property, including, without limitation, computer
equipment, software, keys and access cards, credit cards, files and any
documents (including computerized data and any copies made of any computerized
data or software) containing information concerning the Company, its business
or its business relationships (in the latter two cases, actual or prospective).
You also commit to deleting and finally purging any duplicates of files or
documents that may contain Company information from any computer or other
device that remains your property after the Termination Date.  In the event that you discover that you
continue to retain any such property, you shall return it to the Company
immediately.

 

3

 

6.                                       Re-affirmation
of Confidentiality and Non-Compete Agreement

 

You
acknowledge that you and the Company entered into a Confidentiality &
Non-Compete Agreement on or about June 30, 2002 (the “Confidentiality &
Non-Competition Agreement”), a copy
of which is attached at Exhibit B.  You reaffirm the commitments made by you to
the Company in the Confidentiality & Non-Competition Agreement and
acknowledge that it remains in full force and effect notwithstanding any
changes in your duties, job title or compensation that have occurred since you
and the Company first entered into the Confidentiality &
Non-Competition Agreement.  You further
understand and agree that the Confidentiality and Non-Competition Agreement
contains certain provisions that survive the termination of your employment,
specifically Section 1 (Confidential Information), Section 2 (Work
Product), Section 3 (Returning of Company Property) and Section 5
(Covenant Against Competition).  You
acknowledge that you will abide by these provisions.

 

7.                                       Release
of Claims

 

In
consideration for, among other terms, the payments and benefits described in
Sections 2 and 3, to which you acknowledge you would otherwise not be entitled,
you voluntarily release and forever discharge the Company, its affiliated and
related entities, its and their respective predecessors, successors and
assigns, its and their respective employee benefit plans and fiduciaries of
such plans, and the current and former officers, directors, shareholders,
employees, attorneys, accountants and agents of each of the foregoing in their
official and personal capacities (collectively referred to as the “Releasees”)
generally from all claims, demands, debts, damages and liabilities of every
name and nature, known or unknown (“Claims”) that, as of the date when
you sign this Agreement, you have, ever had, now claim to have or ever claimed
to have had against any or all of the Releasees.  This release includes, without limitation,
all Claims:

 

	
  ·

  	
  relating to your employment by and termination of employment with the
  Company;

  
	
  ·

  	
  of wrongful discharge;

  
	
  ·

  	
  of breach of contract, including, but not limited to the Employment
  Agreement;

  
	
  ·

  	
  of retaliation or discrimination under federal, state or local law
  (including, without limitation, Claims of age discrimination or retaliation
  under the Age Discrimination in Employment Act, Claims of disability
  discrimination or retaliation under the Americans with Disabilities Act, and
  Claims of discrimination or retaliation under Title VII of the Civil Rights
  Act of 1964);

  
	
  ·

  	
  under any other federal or state statute;

  
	
  ·

  	
  of defamation or other torts;

  
	
  ·

  	
  of violation of public policy;

  
	
  ·

  	
  for wages, bonuses, incentive compensation, stock, stock options,
  vacation pay or any other compensation or benefits; and

  
	
  ·

  	
  for damages or other remedies of any sort, including, without
  limitation, compensatory damages, punitive damages, injunctive relief and
  attorney’s fees;

  

 

provided,
however, that this release shall not affect (i) your vested rights under
the Company’s Section 401(k) plan and
under the Plans and the Award Agreements, as modified by Section 3 

 

4

 

herein, (ii) your rights as an officer or former officer of the Company to indemnification
under existing law or the Company’s by-laws, (iii) your rights as an officer or former officer of the Company
under Article V of the Company’s by-laws, (iv) any
claim for coverage under any applicable directors’ and officers’ liability
insurance policy or policies, (v) any claim that cannot be waived under
applicable law, (vi) any rights that you have solely as a stockholder of
the Company, or (vii) your rights under this Agreement.

 

You agree that
you shall not seek or accept damages of any nature, other equitable or legal
remedies for your own benefit, attorney’s fees, or costs from any of the
Releasees with respect to any Claim released by this Agreement.  As a material inducement to the Company to
enter into this Agreement, you represent that you have not assigned to any third
party and you have not filed with any agency or court any Claim released by
this Agreement.

 

8.                                       Nondisparagement

 

You agree not to make any disparaging statements concerning the Company
or any of its affiliates or current or former officers, directors,
shareholders, employees or agents.  You
further agree that you shall not voluntarily provide information to or
otherwise cooperate with any individual or entity that is contemplating or
pursuing litigation against any of the Releasees, or that is undertaking any
investigation or review of any of the Releasees’ activities or practices; provided, however, that you may participate in or otherwise
assist in any investigation or inquiry conducted by the EEOC, the Massachusetts
Commission Against Discrimination, the United States Department of Justice or
any other federal or state law enforcement agency.  The Company also agrees that it will not
instruct or encourage any of its employees, officers, directors or shareholders
to make any disparaging statements concerning you.  These nondisparagement obligations also shall
not in any way affect any obligation to testify or to otherwise respond
truthfully in any legal proceeding, investigation or inquiry or to comply with
requirements to make accurate disclosures. 
These obligations also shall not prohibit you from pursuing any Claim
that you may have against the Releasees that you are not releasing pursuant to Section 7
above.

 

9.                                       Communications Concerning Your Separation

 

If asked about the circumstances of your separation of employment with
the Company, you, the Company and any representatives of the Company who are
aware of the existence and terms of this Agreement shall state that you
resigned and shall not make any further comment about your employment
separation, other than any comment that is consistent with the public
statements of the Company about the separation and any comment that has
otherwise already been authorized or approved by you and the Company; provided
that this shall not prohibit you or the Company, or any of its representatives,
from testifying truthfully in any legal proceeding, providing truthful
information in response to a request from a governmental agency, or providing
truthful information in response to a request for information in connection
with your application for employment with another employer.

 

5

 

10.                                 [Intentionally omitted]

 

11.                                 Future Cooperation

 

You agree to cooperate reasonably with the Company and all of its
affiliates (including its and their outside counsel) in connection with the
contemplation, prosecution and defense of all phases of existing, past and
future litigation about which the Company reasonably believes you may have
knowledge or information.  For that
purpose, you further agree to make yourself available at mutually convenient
times during and outside of regular business hours as reasonably deemed
necessary by the Company’s counsel.  The
Company shall not utilize this Section 11 to require you to make yourself
available to an extent that would unreasonably interfere with other employment,
consulting or non-profit-organization responsibilities that you may have.  You agree to appear without the necessity of
a subpoena to testify truthfully in any legal proceedings in which the Company
calls you as a witness.  The Company
shall also reimburse you for any pre-approved reasonable business travel
expenses that you incur on the Company’s behalf as a result of your litigation
cooperation services, after receipt of appropriate documentation consistent
with the Company’s business expense reimbursement policy.  Notwithstanding the foregoing, nothing herein
shall require you to make yourself available to the Company or its affiliates
(including its and their outside counsel) with respect to a matter if you have
been criminally indicted with respect to such matter.  Additionally, nothing in this Section shall
require you to waive your attorney-client privilege or other evidentiary
privilege with respect to any matter.

 

12.                                 Suspension or Termination of Payments

 

In the event that you fail to materially comply with any of your
obligations under this Agreement, in addition to any other legal or equitable
remedies it may have for such breach the Company shall have the right to
terminate or suspend its payments to you under this Agreement.  The termination or suspension of such
payments in the event of such breach by you will not affect your continuing
obligations under this Agreement. 
Notwithstanding the foregoing, this provision shall not apply to the
extent that your breach of this Agreement consists of initiating a legal action
in which you contend that the release set forth in Section 7 is invalid,
in whole or in part, due to the provisions of 29 U.S.C. §626(f).

 

13.                                 Legal Representation

 

This Agreement is a legally binding document and your signature will
commit you to its terms.  You acknowledge
that you have been advised to discuss all aspects of this Agreement with your
attorney, that you have in fact retained a personal attorney who has reviewed
this Agreement and represented you concerning it, that you have carefully read
and fully understand all of the provisions of this Agreement and that you are
voluntarily entering into this Agreement.

 

14.                                 Absence of Reliance

 

In signing this Agreement, you are not relying upon any promises or
representations made by anyone at or on behalf of the Company other than as set
forth or referred to in this Agreement.

 

6

 

15.                                 Arbitration of Disputes.

 

Any controversy or claim arising out of your employment, the
termination of that employment (including, without limitation, any claims of
unlawful employment discrimination whether based on age or otherwise) or
relating to this Agreement or the breach thereof shall, to the fullest extent
permitted by law, be settled by arbitration in any forum and form agreed upon
by the parties or, in the absence of such an agreement, under the auspices of
the American Arbitration Association (“AAA”) in Boston, Massachusetts in
accordance with the Employment Dispute Resolution Rules of the AAA,
including, but not limited to, the rules and procedures applicable to the
selection of arbitrators.  In the event
that any person or entity other than you or the Company may be a party with
regard to any such controversy or claim, such controversy or claim shall be
submitted to arbitration subject to such other person or entity’s
agreement.  Judgment upon the award
rendered by the arbitrator may be entered in any court having jurisdiction
thereof.  This Section 15 shall be
specifically enforceable. Notwithstanding the foregoing, this Section 15
shall not preclude either party from pursuing a court action in the state or
federal courts of Massachusetts for the sole purpose of obtaining a temporary
restraining order or a preliminary injunction in circumstances in which such
relief is appropriate, including but not limited to enforcement of the Company’s
rights pursuant to Section 6 of this Agreement; provided that any other
relief shall be pursued through an arbitration proceeding pursuant to this Section 15.

 

16.                                 Enforceability

 

If any portion or provision of this Agreement (including, without
limitation, any portion or provision of any section of this Agreement) shall to
any extent be declared illegal or unenforceable by a court or arbitrator of
competent jurisdiction, then the remainder of this Agreement, or the
application of such portion or provision in circumstances other than those as
to which it is so declared illegal or unenforceable, shall not be affected
thereby, and each portion and provision of this Agreement shall be valid and
enforceable to the fullest extent permitted by law.

 

17.                                 Waiver

 

No waiver of any provision of this Agreement shall be effective unless
made in writing and signed by the waiving party.  The failure of any party to require the
performance of any term or obligation of this Agreement, or the waiver by any
party of any breach of this Agreement, shall not prevent any subsequent
enforcement of such term or obligation or be deemed a waiver of any subsequent
breach.

 

18.                                 Injunctive Relief

 

Notwithstanding any provisions contained in Section 15 of this
Agreement, you agree that it would be difficult to measure any harm caused to
the Company that might result from any breach by you of your promises set forth
in Sections 5, 6, 7, 8, 9 or 11 and the Company agrees that it would be
difficult to measure any harm caused to you that might result from any breach
by the Company of its promises in Sections 8, 9 or 11 and that in any event (in
either case) money damages would be an inadequate remedy for any such
breach.  Accordingly, you agree that if 

 

7

 

you breach, or propose to breach, any portion of your obligations under
Sections 5, 6, 7, 8, 9 or 11, the Company shall be entitled, in addition to all
other remedies it may have, to an injunction or other appropriate equitable
relief to restrain any such breach, without showing or proving any actual
damage to the Company and without the necessity of posting a bond; and the
Company agrees that if it breaches, or proposes to breach, any portion of its
obligations under Section 8, 9 or 11, you shall be entitled, in addition
to all other remedies you may have, to an injunction or other appropriate
equitable relief to restrain any such breach, without showing or proving any
actual damage to you and without the necessity of posting a bond.  In the event that the Company prevails in any
action to enforce Sections 5, 6, 7, 8, 9 or 11, then you also shall be liable
to the Company for attorney’s fees and costs incurred by the Company in
enforcing such provision(s).  In the
event that you prevail in any action to enforce Sections 8, 9 or 11, then the
Company also shall be liable to you for attorney’s fees and costs incurred by
you in enforcing such provision(s).

 

19.                                 Governing Law; Interpretation

 

This Agreement shall be interpreted and enforced under the laws of the
Commonwealth of Massachusetts, without regard to conflict of law
principles.  In the event of any dispute,
this Agreement is intended by the parties to be construed as a whole, to be
interpreted in accordance with its fair meaning, and not to be construed
strictly for or against either you or the Company or the “drafter” of all or
any portion of this Agreement.

 

20.                                 Entire Agreement

 

This Agreement constitutes the entire agreement, and supersedes any
previous agreements or understandings, between you and the Company except the
Confidentiality and Non-Competition Agreement and any agreements under which
you may continue to hold rights under the provisions of Section 7 hereof.

 

21.                                 Time for Consideration; Effective Date

 

You have the opportunity to consider this Agreement for twenty-one (21)
days before signing it.  To accept this
Agreement, you must return a signed original of this Agreement so that it is
received by the undersigned at or before the expiration of this twenty-one (21)
day period.  If you sign this Agreement
within less than twenty-one (21) days of the date of its delivery to you, you
acknowledge by signing this Agreement that such decision was entirely voluntary
and that you had the opportunity to consider this Agreement for the entire
twenty-one (21) day period.  For the
period of seven (7) days from the date when this Agreement becomes fully
executed, you have the right to revoke this Agreement by written notice to the
undersigned.  For such a revocation to be
effective, it must be delivered so that it is received by the undersigned at or
before the expiration of the seven (7) day revocation period.  This Agreement shall not become effective or
enforceable during the revocation period. 
This Agreement shall become effective on the first business day
following the expiration of the revocation period (the “Effective Date”).

 

8

 

22.                                 Counterparts

 

This Agreement may be executed in any number of counterparts, each of
which when so executed and delivered shall be taken to be an original, but all
of which together shall constitute one and the same document.

 

[Remainder of page intentionally left blank]

 

9

 

Please indicate your agreement to the terms of this Agreement by
signing and returning to me the original of this letter within the time period
set forth above.

 

Very truly yours,

 

NEUROMETRIX, INC.

 

 

	
  By:

  	
  /s/ Shai N. Gozani, M.D. Ph.D.

  	
   

  	
  May 1, 2008

  
	
   

  	
  Shai N. Gozani, M.D. Ph.D.

  	
   

  	
  Date

  
	
   

  	
  Chief Executive Officer and President

  	
   

  	
   

  

 

	
  Enclosures:

  	
  Exhibit A – Summary of Vested Stock
  Options

  
	
   

  	
  Exhibit B – Confidentiality and
  Non-Competition Agreement

  

 

You are advised to consult with an attorney
before signing this Agreement.  The foregoing
is agreed to and accepted by:

 

 

	
  /s/ Gary L. Gregory

  	
   

  	
  May 1, 2008

  
	
  Gary L. Gregory

  	
   

  	
  DateExhibit
10.4

 

***Text
Omitted and Filed Separately

with the
Securities and Exchange Commission.

Confidential
Treatment Requested

Under 17
C.F.R. Sections 200.80(b)(4)

and
240.24b-2.

 

April 16, 2008

 

Merck & Co., Inc.

One Merck Drive 

P.O. Box 100

Whitehouse Station, NJ  08889-0100

Attention:                 Office of the Secretary, WS3A-65

Chief Licensing Officer, WS2A-30

 

Re:                             License and Collaboration
Agreement dated as of June 22, 2005 (the  “Collaboration Agreement”)
between Merck & Co., Inc. (“Merck”) and Metabasis Therapeutics, Inc.
(“Metabasis”)

 

Ladies and Gentlemen:

 

This Letter (this “Letter”)
confirms the understanding of Merck and Metabasis regarding certain matters
relating to the Collaboration Agreement and is intended to be legally binding
on both parties.  Capitalized terms used
but not otherwise defined in this Letter
shall have the meanings provided in the Collaboration Agreement.  The parties agree to extend the Research
Term, which is currently scheduled to terminate on June 21, 2008, on the
terms and conditions specified in this Letter.

 

The parties hereby acknowledge and agree that (a) as
contemplated by [...***...] of the Collaboration Agreement, the Research Term is
hereby extended for one additional year from June 21, 2008 through June 21,
2009 (such extended time period being referred to herein as the “Extension Period”), and (b) notwithstanding anything
to the contrary in [...***...] of the Collaboration Agreement, (i) unless
otherwise agreed to by the parties in writing, Metabasis shall dedicate [...***...]
FTEs to the Collaboration during the Extension Period, which FTEs shall be
funded by Merck in accordance with [...***...] of the Collaboration Agreement, and (ii) the
provisions in [...***...] of the Collaboration Agreement regarding Aggregate FTEs
and Additional Metabasis FTEs shall be inapplicable during the Extension
Period.  The parties further agree that,
pursuant to [...***...] of the Collaboration Agreement, the JRC will amend the
Research Plan to reflect activities to be conducted during the Extension
Period.  It is the intent of the parties
that for the duration of the Extension Period, to the extent reasonably
possible, [...***...].

 

Except as amended by this Letter, the terms and
conditions of the Collaboration Agreement shall remain in full force and effect
in all other respects, unless further amended by written agreement in
accordance with Section 13.3 of the Collaboration Agreement.  On and after the effectiveness of this
Letter, each reference in the Collaboration Agreement to “this Agreement”, “hereunder”,
“hereof”, “herein” or words of like import referring to the Collaboration
Agreement shall mean and be a reference to the Collaboration Agreement as
amended by this Letter.  The parties
hereby further agree

 

***Confidential Treatment
Requested

 

 

that the Dispute Resolution provisions of Article 12 of the
Collaboration Agreement and the terms and conditions set forth in Article 13
of the Collaboration Agreement, including without limitation, the Governing Law
provisions of Section 13.2 and the Assignment and Change of Control
provisions of Section 13.6, shall apply to this Letter as if fully set
forth herein.

 

This Letter may be executed (including, without limitation, by
facsimile signature) in two counterparts, each of which shall be deemed an
original, but both of which together shall constitute one and the same
instrument.

 

If the foregoing is acceptable to you, please sign this Letter in the space provided below
and return it to me.

 

	
   

  	
  Sincerely,

  
	
   

  	
   

  
	
   

  	
  METABASIS THERAPEUTICS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
       /s/
  Paul Laikind, Ph.D.

  
	
   

  	
  Name: 

  	
   Paul Laikind,
  Ph.D.

  
	
   

  	
  Title:

  	
     President
  and CEO

  
					

 

 

Agreed to and accepted as of the
date first set forth above:

 

MERCK & CO., INC.

 

 

	
  By:

  	
        /s/
  Mervyn Turner, PhD

  	
   

  
	
   

  	
   

  
	
  Name:

  	
  Mervyn Turner, PhD

  	
   

  
	
   

  	
   

  	
   

  
	
  Title:

  	
  Senior Vice President,
  Worldwide

  	
   

  
	
   

  	
  Licensing and Exmternal
  Research

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]